Liraglutide's LEAD-2 trial replicated in claims data to validate real-world evidence methods

Validating real-world evidence (RWE) against randomized controlled trials (RCTs) is crucial for expanding evidence-based medicine. Traditional RCTs offer high internal validity but often lack generalizability to diverse patient populations and real-world clinical practice. Healthcare claims data represent a vast, untapped resource for RWE, yet methods for robust analysis and confidence in their findings remain under active development. Replicating established RCTs like LEAD-2 using claims data helps bridge this gap, assessing the reliability and applicability of RWE for clinical decision-making.

This study replicated the LEAD-2 Diabetes Trial, which originally assessed Liraglutide for Type 2 Diabetes Mellitus, using existing healthcare claims data. The methodology involves large-scale emulation of established randomized controlled trials (RCTs) to evaluate the reliability of real-world data (RWD) analyses. The primary objective is to determine for which clinical questions RWD analyses can be conducted with confidence and to establish best practices for implementing such studies. This forms part of a broader initiative to build an empirical evidence base for RWD.